Related Experiment Videos

Clinical trials with biological response modifiers in rheumatic diseases

M A Scheinberg¹

¹Instituto do Cancer Arnaldo Vieira de Carvalho, São Paulo, Brazil.

The Journal of Rheumatology

|July 1, 1988

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.

Lupus·2016

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Annals of the rheumatic diseases·2014

Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus.

Lupus·2006

Serum vascular endothelial growth factor in late rheumatoid arthritis.

Clinical and experimental rheumatology·2002

Interleukin 6: a possible marker of disease activity in adult onset Still's disease.

Clinical and experimental rheumatology·1996

Immunological status of ENL (erythema nodosum leprosum) patients: its relationship to bacterial load and levels of circulating IL-2R.

Revista do Instituto de Medicina Tropical de Sao Paulo·1996

See all related articles